Brokerages Set Humacyte, Inc. (NASDAQ:HUMA) Price Target at $11.00

Humacyte, Inc. (NASDAQ:HUMA) has earned an average rating of “Buy” from the eight brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $13.00.

Several research analysts have recently weighed in on the stock. TD Cowen reiterated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. BTIG Research reiterated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a report on Thursday, November 21st. Finally, EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a report on Monday, September 9th.

Insider Activity at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the sale, the director now owns 1,992,253 shares in the company, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the sale, the chief executive officer now owns 1,730,884 shares in the company, valued at $7,615,889.60. This represents a 13.12 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,014,998 shares of company stock worth $9,725,449. Company insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

Hedge funds have recently made changes to their positions in the company. nVerses Capital LLC purchased a new stake in shares of Humacyte during the second quarter valued at approximately $28,000. Concurrent Investment Advisors LLC purchased a new stake in shares of Humacyte during the third quarter valued at approximately $75,000. Principal Financial Group Inc. purchased a new stake in shares of Humacyte during the second quarter valued at approximately $83,000. FORA Capital LLC purchased a new stake in shares of Humacyte during the third quarter valued at approximately $96,000. Finally, Profund Advisors LLC purchased a new stake in shares of Humacyte during the second quarter valued at approximately $97,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Trading Up 3.5 %

Shares of HUMA stock opened at $4.43 on Friday. The firm has a market cap of $557.56 million, a P/E ratio of -3.31 and a beta of 1.47. Humacyte has a 1-year low of $2.43 and a 1-year high of $9.97. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. The firm’s 50-day simple moving average is $5.28 and its 200-day simple moving average is $6.19.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.